Godaddy Inc vs Mesoblast Limited — how do they compare? Godaddy Inc trades at $90.78 (market cap $11.49B), while Mesoblast Limited trades at $16.86 (market cap $2.21B). The key difference: Godaddy Inc is far larger — about 5.2× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals.
| GDDY | MESO | |
|---|---|---|
Market Cap | $11.49B | $2.21B |
Sector | Technology | Technology |
52-Week High | $148.88 | $20.96 |
52-Week Low | $75.07 | $12.88 |
Enterprise Value | $14.18B | $2.21B |
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $90.78, down 0.78% on the day, with a bearish technical signal and mixed sentiment due to ongoing securities investigations. Fundamentally, the company shows strength with consistent earnings beats, revenue growth to $4.95B in 2025, and robust profitability margins. The stock trades at a P/E of 13.48, below the sector average, while analyst consensus targets $112.13, implying significant upside.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but near-term volatility is likely from legal overhangs and technical resistance. Key risks include potential litigation outcomes and competitive pressures in web services. Upside hinges on continued execution and clearing regulatory concerns.
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Trailing returns across standard periods
Latest headlines on both assets
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →